Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
- Registration Number
- NCT01225172
- Lead Sponsor
- Bristol-Myers Squibb
- Brief Summary
The purpose of this study is to evaluate oral doses of BMS-754807 in combination with letrozole or BMS-754807 alone are safe and efficacious in locally advanced or metastatic hormone receptor positive breast cancer subjects who have progressed with prior non-steroidal aromatase inhibitor treatment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- Female
- Target Recruitment
- 77
- Postmenopausal women with hormone receptor-positive and HER-2 negative breast cancer
- Disease progression following non-steroidal aromatase inhibitor treatment
- Known symptomatic brain metastasis
- Medical condition requiring chronic steroids
- History of Type 1 or 2 Diabetes
- Uncontrolled or significant cardiovascular (CV) disease
- Concomitant second malignancies
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description BMS-754807 + letrozole letrozole - BMS-754807 + letrozole BMS-754807 - BMS-754807 BMS-754807 -
- Primary Outcome Measures
Name Time Method Progression Free Survival Rate at 24 Weeks 24 weeks after initiation of study treatment Progression free survival (PFS) rate at 24 weeks after treatment with BMS 754807/letrozole was to be calculated as the total number of subjects neither progressed nor died after 24 weeks of treatment divided by the total number of subjects (with measurable or non-measurable disease) randomized/assigned to combination treatment arm and treated. In participants with measurable disease Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) criteria was to be used to assess disease progression.This outcome was not measured due to early termination of the study.
- Secondary Outcome Measures
Name Time Method The Objective Response Rate (ORR) in Participants With Measurable Disease 24 weeks after initiation of study treatment ORR is defined as the number of participants with best overall response (OR) of confirmed complete response (CR) or partial response (PR) divided by the number of participants who received treatment.
Participants were to be evaluated for tumor response per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions.: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. This outcome measure was not met due to early termination of the studyNumber of Participants With Adverse Events (AEs), Serious AEs, Non-serious AEs , Discontinuation Due to AEs and Deaths Non-SAEs: Day 1 to 7 days after the participant discontinues study medication or 7 days after the End of Treatment visit (up to 42 months), For SAEs: during the screening period and within 30 days of discontinuation of dosing ,up to 42 months An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a patient or clinical investigation subject administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment.
Changes in Absolute Copy Numbers and Relative Expression of Insulin Receptor Isoform A (IR-A) in Tumor Tissue in Response to Treatment 24 weeks after initiation of study Absolute copy numbers and relative expression of insulin receptor isoforms (IR-A, IR-B) in pre- and posttreatment fresh tumor tissues were to be measured. This outcome was not measured due to early termination of the study.
Duration of Response (DOR) in Participants With Measurable Disease 24 weeks after initiation of study treatment DOR was to be performed to further characterize the response rate at Week 24. Duration of response is defined as the time between the Week 25 date of response and the date of objectively documented disease progression as defined by modified RECIST 1.1 criteria or death, whichever occurs first. DOR could not be assessed due to early termination of the study.
Treatment Failure Rate (TFR) 24 weeks after initiation of study treatment The TFR was to be calculated as the total number of subjects who discontinued the treatment for any reason (including disease progression, treatment toxicity, and death) at 24 weeks divided by the total number of subjects randomized/assigned to the arm and treated. In the monotherapy arm, the TFR was to be assessed while subjects were on monotherapy.
Number of On-study Laboratory Abnormalities: Grade 1-2 Assessed from day 1 up to within 30 days of last dose (Approximately 42 months) Blood and urine samples were obtained at specified times points for laboratory evaluations. Clinical Laboratory Sage Panels included: Hematology: Hemoglobin, Hematocrit, Red blood cell, Total leukocyte count, including differential, Platelet count. Serum Chemistry : Albumin, Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Alkaline phosphatase (ALK-P), Bilirubin, total (TB). Reflex testing of direct (conjugated) and indirect (unconjugated) bilirubin will be ordered if total bilirubin \> 5X ULN, Blood urea nitrogen (BUN or urea), Calcium, Chloride, Cholesterol, Creatinine, serum, Glucose, fasting plasma, Lactate dehydrogenase (LDH), Magnesium, Phosphorus, Potassium, Protein, total, Sodium, Triglycerides, Uric acid Urinalysis, Blood, Glucose, Ketones, Leukocyte esterase, pH, Protein. Laboratory tests were graded using the National Cancer Institute-Common Toxicity Criteria for Adverse Events (CTCAE), Version 4.0 criteria
Number of On-study Laboratory Abnormalities: Grade 3-4 Assessed from day 1 up to within 30 days of last dose (Approximately 42 months) Blood and urine samples were obtained at specified times points for laboratory evaluations. Clinical Laboratory Sage Panels included: Hematology: Hemoglobin, Hematocrit, Red blood cell, Total leukocyte count, including differential, Platelet count. Serum Chemistry : Albumin, Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Alkaline phosphatase (ALK-P), Bilirubin, total (TB). Reflex testing of direct (conjugated) and indirect (unconjugated) bilirubin will be ordered if total bilirubin \> 5X ULN, Blood urea nitrogen (BUN or urea), Calcium, Chloride, Cholesterol, Creatinine, serum, Glucose, fasting plasma, Lactate dehydrogenase (LDH), Magnesium, Phosphorus, Potassium, Protein, total, Sodium, Triglycerides, Uric acid Urinalysis, Blood, Glucose, Ketones, Leukocyte esterase, pH, Protein Laboratory tests were graded using the National Cancer Institute-Common Toxicity Criteria for Adverse Events (CTCAE), Version 4.0 criteria
Trial Locations
- Locations (16)
Oncology Care Associates, P.A.
🇺🇸Wheaton, Maryland, United States
Presbyterian Hospital Cancer Research
🇺🇸Charlotte, North Carolina, United States
University Of Virginia Health System
🇺🇸Charlottesville, Virginia, United States
Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins
🇺🇸Baltimore, Maryland, United States
Masonic Cancer Ctr, University Of Minnesota
🇺🇸Minneapolis, Minnesota, United States
Ut Md Anderson Can Ctr.
🇺🇸Houston, Texas, United States
University Of Chicago Medical Center
🇺🇸Chicago, Illinois, United States
Illinois Cancercare, Pc
🇺🇸Peoria, Illinois, United States
Indiana University Health Goshen Center For Cancer Care
🇺🇸Goshen, Indiana, United States
Univ Of Al At Birmingham
🇺🇸Birmingham, Alabama, United States
Sharp Clinical Oncology Research
🇺🇸San Diego, California, United States
Mayo Clinic Arizona
🇺🇸Scottsdale, Arizona, United States
Duke University Medical Center-Dept Of Medicine
🇺🇸Durham, North Carolina, United States
Mayo Clinic
🇺🇸Rochester, Minnesota, United States
Unv. Of Nc At Chapel Hill
🇺🇸Chapel Hill, North Carolina, United States
University Of Wisconsin
🇺🇸Madison, Wisconsin, United States